UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
|
☒ |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the fiscal year ended December 31, 2020
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO |
Commission File Number 001-39206
Schrodinger, Inc.
(Exact name of Registrant as specified in its Charter)
|
Delaware |
95-4284541 |
|
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
|
120 West 45th Street, 17th Floor New York, NY |
10036 |
|
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including area code: (212) 295-5800
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
Common stock, par value $0.01 per share |
|
SDGR |
|
The Nasdaq Stock Market LLC |
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES ☒NO ☐
Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES ☐ NO ☒
Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). YES ☒ NO ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
|
|||
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒
As of June 30, 2020, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was $2,187,273,894 based upon the closing sale price of the registrant’s common stock on that date.
As of February 26, 2021, the registrant had 60,848,093 shares of common stock and 9,164,193 shares of limited common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2021 Annual Meeting of Stockholders within 120 days of the end of the registrant’s fiscal year ended December 31, 2020. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.
Table of Contents
|
|
|
|
Page |
|
PART I |
|
|
|
|
Item 1. |
|
5 |
|
|
Item 1A. |
|
44 |
|
|
Item 1B. |
|
76 |
|
|
Item 2. |
|
76 |
|
|
Item 3. |
|
76 |
|
|
Item 4. |
|
76 |
|
|
|
|
|
|
|
PART II |
|
|
|
|
Item 5. |
|
77 |
|
|
Item 6. |
|
79 |
|
|
Item 7. |
|
81 |
|
|
Item 7A. |
|
98 |
|
|
Item 8. |
|
98 |
|
|
Item 9. |
|
99 |
|
|
Item 9A. |
|
99 |
|
|
Item 9B. |
|
100 |
|
|
|
|
|
|
|
PART III |
|
|
|
|
Item 10. |
|
101 |
|
|
Item 11. |
|
101 |
|
|
Item 12. |
|
101 |
|
|
Item 13. |
|
101 |
|
|
Item 14. |
|
101 |
|
|
|
|
|
|
|
PART IV |
|
|
|
|
Item 15. |
|
102 |
|
|
Item 16 |
|
106 |
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA
This Annual Report on Form 10-K, or this Annual Report, contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this Annual Report, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” or the negative of these words or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
The forward-looking statements in this Annual Report include, among other things, statements about:
|
|
• |
the potential advantages of our physics-based computational platform; |
|
|
• |
our strategic plans to accelerate the growth of our software business; |
|
|
• |
our research and development efforts for our internal drug discovery programs and our computational platform; |
|
|
• |
the initiation, timing, progress, and results of our internal drug discovery programs or the drug discovery programs of our collaborators; |
|
|
• |
our plans to discover and develop product candidates and to maximize their commercial potential by advancing such product candidates ourselves or in collaboration with others; |
|
|
• |
our plans to leverage the synergies between our businesses; |
|
|
• |
the timing of, the ability to submit applications for and the ability to obtain and maintain regulatory approvals for any product candidates we or one of our collaborators may develop; |
|
|
• |
our drug discovery collaborations and our estimates or expectations regarding any milestone or other payments we may receive from such collaborations, including pursuant to our collaboration with Bristol-Myers Squibb Company; |
|
|
• |
our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash, cash equivalents, and marketable securities; |
|
|
• |
the potential advantages of our drug discovery programs; |
|
|
• |
the rate and degree of market acceptance of our software solutions; |
|
|
• |
the potential impact of the COVID-19 pandemic on our business, operations, liquidity and prospects; |
|
|
• |
the rate and degree of market acceptance and clinical utility of our products; |
|
|
• |
our estimates regarding the potential market opportunity for our software solutions and any product candidate we or any of our collaborators may in the future develop; |
|
|
• |
our marketing capabilities and strategy; |
|
|
• |
our intellectual property position; |
|
|
• |
our ability to identify technologies with significant commercial potential that are consistent with our commercial objectives; |
|
|
• |
our expectations related to the use of our cash, cash equivalents, and marketable securities; |
|
|
• |
our expectations related to the key drivers of our performance; |